STERIS plc Stock
STERIS plc Stock
With 7 Buy predictions and not the single Sell prediction the community is currently very high on STERIS plc.
Pros and Cons of STERIS plc in the next few years
Pros
?
S********** s********
?
B****
?
C******** o* t** e**********
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of STERIS plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| STERIS plc | - | - | - | - | - | - | - |
| Smith & Nephew plc | -1.410% | 6.818% | 10.156% | 2.882% | -0.809% | 0.678% | -18.356% |
| Baxter International | 7.770% | 21.773% | 24.417% | -5.554% | 42.463% | -45.580% | -64.413% |
| Dexcom Inc. | -2.430% | 4.516% | 9.831% | -16.902% | 13.050% | -46.036% | -40.386% |
Comments
STERIS (STE) is now covered by UBS Group AG. They set a "buy" rating on the stock.
Show more
Ratings data for STE provided by MarketBeat
STERIS (STE) had its "overweight" rating reaffirmed by Piper Sandler.
Show more
Ratings data for STE provided by MarketBeat
STERIS (STE) had its "overweight" rating reaffirmed by KeyCorp.
Show more
Ratings data for STE provided by MarketBeat
News
STERIS Q4 Earnings Call Highlights
STERIS (NYSE:STE) reported a stronger fiscal 2026 overall despite a lighter fourth quarter, with executives pointing to record annual revenue, resilient procedure demand and continued pricing
